fashion -WSS

fashion

author：hotspot 2025-09-14 18:32:50 - browse：178

An ALS patient receives support. -- health coverage from STAT — Adobe

Years of polarizing scientific discourse and bruising online debate will come to a head next week when advisers to the Food and Drug Administration weigh in on NurOwn, a potential treatment to slow the progression of ALS that has bitterly divided physicians and patient advocates.

On Sept. 27, a panel of experts will consider the convoluted data supporting the potential approval of NurOwn, a stem-cell therapy the FDA previously refused to even consider. To some physicians, the drug’s failure to show significant benefits in clinical studies leaves approval out of the question. Others, including the influential ALS Association, say NurOwn’s manufacturer, a small biotech firm called BrainStorm Cell Therapeutics, hasn’t disclosed enough information to properly determine the medicine’s value.

Another group of patients and doctors argue that NurOwn’s supporting evidence, while problematic, justifies making it available to the roughly 30,000 ALS patients in the U.S., people for whom there is currently no hope of arresting an incurable disease that gradually erodes motor function and leads to death within about five years of diagnosis.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： Obamacare plans could cover weight loss drugs

WSS

A new drug could help frostbite victims avoid its ravages

Obamacare plans could cover weight loss drugs

A new drug could help frostbite victims avoid its ravages

Opioid cravings were reduced by anti

Abridge raises $150m as clinical notes automation market heats up

The Sacklers, horror, and ‘The Fall of the House of Usher’

explore

fashion

hotspot

Malaria cases in Florida and Texas: Here’s what you need to know

Don't let 'shelved assets' gather dust. Make them into new lifesaving drugs

How to save PrEP access — and even expand it

Hospitals are piloting generative AI tools as regulators play catch

Drug repurposing or repositioning? The language matters

Removing probiotics from the NICU could threaten preemies' health

Medical records are filled with copy

A new drug could help frostbite victims avoid its ravages

DIEP, the 'gold standard' of breast reconstruction, is under threat

Surprise medical billing ban raises prices elsewhere

entertainment

Elevance, SCAN deals highlight health insurer acquisition scrutiny

HPV cancer vaccine study demonstrates efficacy

Medicare Advantage enrollment grows 7.1% to 33.4 million people

Will General Catalyst be the first of many hospital takeovers?

White House calls on federal agencies to crack down on AI abuses

AbbVie CEO Gonzalez to step down after a decade fiercely defending Humira

entertainment

explore

leisure time

knowledge